| Literature DB >> 17237811 |
F Demichelis1, K Fall, S Perner, O Andrén, F Schmidt, S R Setlur, Y Hoshida, J-M Mosquera, Y Pawitan, C Lee, H-O Adami, L A Mucci, P W Kantoff, S-O Andersson, A M Chinnaiyan, J-E Johansson, M A Rubin.
Abstract
The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95% confidence interval=1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high ets-related [corrected] gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17237811 DOI： 10.1038/sj.onc.1210237
Source DB: PubMed Journal: Oncogene ISSN： 0950-9232 Impact factor: 9.867